Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561755 · ClinicalTrials.gov registry record · Phase 4
A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy
A Phase 4 study, sponsored by David M. Simpson.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT01561755 is a Phase 4 study that was terminated before completion, run by David M. Simpson. The registered enrollment target is 12 participants.
The verdict
NCT01561755, a Phase 4 study, was terminated before completion, sponsored by David M. Simpson.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
Interventions
- DRUG Placebo
- DRUG Intravenous Immunoglobulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01561755
The ClinicalTrials.gov registry entry for NCT01561755 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David M. Simpson, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01561755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01561755 about?
NCT01561755 is a clinical study titled "A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy". The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
What is the current status of trial NCT01561755?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2012-02. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01561755?
The interventions under investigation include: Placebo (DRUG), Intravenous Immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT01561755?
This trial is sponsored by David M. Simpson, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.